China-focused Concord Medical gets management buyout offer


Management has offered to buy Beijing-based radiotherapy and diagnostic firm Concord Medical Services ($CCM) in a $228 million bid.

Jianyu Yang, chairman and CEO of Concord and a finance vehicle he controls, Morgancreek Investment Holdings, along with Blue Ocean Management, made the July 11 privatization offer of $5.19 for each of the 9 million American Depositary Shares. That amounted to a 34% premium to the previous day's closing price for the 19% stake the firm didn't hold.

In addition to the Carlyle investment, Solar Honor also has shares.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

NYSE-listed Concord Medical has plans afoot to add to its services by developing its own cancer hospitals under the name Meizhongjiahe. One unit has already opened in China and more are planned to augment its income from contracts with 74 hospitals in China.

The expansion, and a related effort to grow a medical tourism business out of a hospital the company owns in Singapore, form the backbone of a management plan to grow as China opens up to more private medical care.

China has approved and encouraged private hospital investment as a way to provide greater depth of therapeutic services and to take pressure off an often overwhelmed public network.

Carlyle has been a major player in the space, most recently as part of a group in March that saw Meinian Onehealth Healthcare buy Ciming Health Checkup Management for $415 million as part of a move to consolidate medical exam and disease screening services in China.

- here's the release

Related Articles:
Carlyle-backed Meinian Onehealth snaps up Ciming for $415M
Chinese political body wants more progress on hospital reforms


Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.